Lipid nanoparticles are nanoparticles made of lipids. These are spherical vesicles made up of ionizable lipids and lipid nanoparticles that help to protect and transfer mRNA to cells.
Acceptance of Lipid Nanoparticles (LNPs) in COVID-19 Fight Drives Growth of the Lipid Nanoparticles CDMO Market
Lipids are substances that are essential for mRNA-based treatments since they serve as the basis for living cells. A lipid nanoparticle (LNP) made of specific lipids surrounds the mRNA. The LNP safeguards the mRNA and delivers it into the cell, where it is released.
“The effectiveness of mRNA vaccines against COVID-19 boosted the demand for lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As projects entered the commercialization stage from the clinical trial stage, developers were more challenged to ensure consistency in LNP formulation as the necessary quantities increased.”-Senior Scientist, Lipid Nanoparticle CDMO, USA
A robust pipeline of drugs related to lipid nanoparticles (LNP) drives demand for lipid nanoparticles CDMOs.
LNPs can carry unstable genetic resources like mRNA and gene treatments into cells while safeguarding them.
- In May 2023, Inventage Lab signed a co-development and manufacturing (CDMO) commercialization agreement with EuBiologics for LNP production.
Investments by PE Companies in Lipid Nanoparticle CDMOs Fuels the Lipid Nanoparticles CDMO Market Growth
Many private equity firms have increased their investments in Lipid Nanoparticles CDMOs, citing the attractive development potential of the global lipid nanoparticles CDMO market.
- In June 2023, Vernal Biosciences, an mRNA and LNP Contract CDMO announcedthat it had completed a $20MM funding round led by Ampersand Capital Partners and Charles River Labs
- In August 2022, Ampersand Capital Partners, a private equity firm specialized in growth equity investments in the healthcare business, announced a majority recapitalization of Phosphorex
Competitive Landscape Analysis: Lipid Nanoparticles CDMO Market
Evonik Health Care, Merck, CordenPharma, Phosphorex, eTheRNA Manufacturing, Fujifilm Pharmaceuticals, Helix Biotech, BIOVECTRA, Vernal Biosciences etc
Key Market Players Adopt Aggressive Growth Strategies to Establish Their Foothold in the Lipid Nanoparticles CDMO Market
In March 2023, Evonik open new facilities in Lafayette, Indiana, in the United States and Hanau, Germany for pharmaceutical lipids.
In March 2022, CordenPharma increased its lipid manufacturing capacity to support mRNA vaccines.
Global lipid nanoparticles CDMO market is expected to expand due to their increasing application in vaccines, cancer treatments, gene therapy products, and aggressive market strategies.
Explore Detailed Research Report on Lipid Nanoparticles CDMO Market @ https://meditechinsights.com/lipid-nanoparticles-cdmo-market/